MEDI0618
Sponsors
AbbVie Deutschland GmbH & Co. KG, AstraZeneca, AbbVie
Conditions
Chronic PainMigraine
Phase 1
A Study of the Safety, Tolerability and Pharmacokinetics of MEDI0618 in Healthy Volunteers
CompletedNCT04198558
Start: 2019-11-29End: 2022-02-23Updated: 2023-10-16
Multiple Dose Study of Safety and Pharmacokinetics of MEDI0618 in Healthy Volunteers
CompletedNCT05714254
Start: 2022-12-12End: 2023-12-12Updated: 2024-01-05
Phase 2
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
RecruitingNCT06602479
Start: 2024-10-07End: 2027-05-07Target: 488Updated: 2026-05-19
A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants with Episodic Migraine
RecruitingCTIS2024-512904-21-00
Start: 2025-12-10Target: 448Updated: 2026-01-13